NSSG Chemotherapy Protocol
DRUG REGIMEN Days 1 to 7 G-CSF subcutaneous. As per local policy (up to 28 days). (e.g. Filgrastim 0.5microgram/kg/day) Days 2 to 6 FLUDARABINE 30 mg/m2 daily in 100 mL sodium chloride 0.9% intravenous infusion over 30 minutes (5 doses). Fludarabine infusion must precede the administration of cytarabine by 4 hours.
Download NSSG Chemotherapy Protocol
Information
Domain:
Source:
Link to this page:
Documents from same domain
CYCLOPHOSPHAMIDE / BORTEZOMIB/ …
nssg.oxford-haematology.org.ukMyeloma group This is a controlled document and therefore must not be changed of MM.11 CyBorDex- Amyloidosis Authorised by …
Cyclophosphamide priming prior to PBSC harvest
nssg.oxford-haematology.org.ukDepartment of Clinical Haematology Oxford BMT Programme B.2.20b Page 1 of 3 May 2017 V.5.4 Cyclo prime for Myeloma PSBC Harvest Authorised by: Dr Karthik Ramasamy
ATTENUATED CYCLOPHOSPHAMIDE, THALIDOMIDE & …
nssg.oxford-haematology.org.ukMyeloma group This is a controlled document and therefore must not be changed MM.9 CTD - attenuated Authorised by Myeloma lead Dr. Karthik Ramasamy July 2017
Guidelines for the Management of Hypomagnesaemia …
nssg.oxford-haematology.org.ukDepartment of Clinical Haematology H.95 Page 2 of 5 November 2015 V.1.0. Guidelines for the management of hypomagnesaemia in Adult Clinical Haematology
Oxford Myeloma Group
nssg.oxford-haematology.org.ukMM.50 VTDPACE/DTPACE Authorised by Myeloma lead Dr. Karthik Ramasamy June 2022 V. 2.0 of 10 Days Drug Dose Route Comments 1 to 4 Dexamethasone 40 mg daily Oral Continuous daily/ If PBSC harvest planned only for days 1 to 4 Thalidomide (See note below) Start 50 mg and increase up to 100 mg as tolerated Oral Nocte 1 to 4
MATRix (High dose METHOTREXATE, high dose CYTARABINE ...
nssg.oxford-haematology.org.uk- Reduce thiotepa dose to 75% - Reduce methotrexate to 2g/m2 Haematological toxicity In case if inadequate bone marrow recovery (i.e. neutrophils < 1.5x109/L and platelets < 90x109/L on the intended day of re-treatment, delay cycle until counts satisfactory. Doses of the chemotherapy
ISATUXIMAB WITH POMALIDOMIDE AND …
nssg.oxford-haematology.org.ukvolume Initial rate Absence of infusion reaction Rate increment Maximum rate First infusion 250 mL 25 mL/ hour For 60 minutes 25 mL/hour every 30 minutes 150 mL/ hour Second infusion 250 mL 50 mL/ hour For 30 minutes 50 mL/ hour for 30 minutes then increase by 100 mL/ hr every 30 minutes 200 mL/ hour Subsequent infusions
ATRA + ARSENIC TRIOXIDE
nssg.oxford-haematology.org.ukArsenic Trioxide infusion duration may be extended up to 4 hours if vasomotor reactions, e.g. flushing, tachycardia and dizziness, are observed. If patients suffer severe symptoms or hypotension then the infusion should be stopped until recovery and then recommenced at a
High dose METHOTREXATE (high grade NHL CNS …
nssg.oxford-haematology.org.ukadults receiving high-dose methotrexate chemotherapy (doses >1g/m2) - Who develop significant deterioration in renal function (>1.5x ULN and rising, or the presence of oliguria) OR - Have toxic plasma methotrexate level AND - Have been treated with all standard rescue and supportive measures AND
ESHAP and R-ESHAP
nssg.oxford-haematology.org.uk2. Record stage of disease - contrast enhanced CT scan (neck, chest, abdomen and pelvis), ... In order to eliminate the risk of transmitting infective ... After 1-2 cycles with CT or PET-CT. Lymphoma group This is a controlled document and therefore must …
Related documents
DRUG NAME: Hydroxyurea - BC Cancer
www.bccancer.bc.caDRUG NAME: Hydroxyurea SYNONYM(S): hydroxycarbamide 1 ... The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event ... increased cytarabine therapeutic and toxic effects ...
DRUG NAME: Cytarabine - BC Cancer
www.bccancer.bc.caCytarabine DRUG NAME: Cytarabine SYNONYM(S): 1-B-arabinofuranosylcytosine, 1 arabinosylcytosine, 1 ara-C, 1 cytosine arabinoside 1 COMMON TRADE NAME(S): CYTOSAR® CLASSIFICATION: antimetabolite 1 Special pediatric considerations are noted when applicable, otherwise adult provisions apply.
DRUG NAME: Fludarabine
www.bccancer.bc.caDRUG NAME: Fludarabine SYNONYM(S): 9-B-D-arabinofuranosyl-2-fluoroadenine 5’-monophosphate, 1 FAMP, 2,3 2-fluoro-ara-A Monophosphate, 3 2-fluoro-ara-AMP, 1,3 fludarabine phosphate, 1 NSC-312887 1. COMMON TRADE NAME(S): FLUDARA CLASSIFICATION: antimetabolite. 1. Special pediatric considerations are noted when applicable, otherwise adult ...
CYTARABINE (ARA-C) HIGH DOSE
nssg.oxford-haematology.org.ukCYTARABINE Prof HD Authorised by Myeloid Lead Adam Mead Oct 2019 Version 4.2 1 of 3 CYTARABINE (ARA-C) HIGH DOSE INDICATION Consolidation chemotherapy for AML in remission. Consider dose reduction to 1.5g/m2 for patient ≥60 years old and for patient under 60 years old with co-morbidities at the discretion of clinician and as discussed at the MDT.
DRUG NAME Gemcitabine - BC Cancer
www.bccancer.bc.caDRUG NAME: Gemcitabine ... Gemcitabine, a pyrimidine analog, is structurally similar to cytarabine, but has a wider spectrum of antitumour activity due to its different cellular pharmacology and mechanism of action.1 Gemcitabine is metabolized intracellularly to two active metabolites, gemcitabine diphosphate (dFdCDP) and gemcitabine ...
Blue Cross and BCN utilization management medical drug …
www.bcbsm.comLists any preferred products that a member must try and fail before receiving a drug. When a cell is blank, there is no preferred product information for that drug. Note: Medical benefit drug policies are a source for Blue Cross and BCN medical policy information. Medical policies are not to be used to determine benefits or reimbursement.
2021 Service Benefit Plan Specialty Drug List
www.myprime.comThe specialty drug list is updated monthly and is subject to change without notice. If you are a member or health-care provider and have specialty drug-specific questions, please call 1- 888-346-3731 weekdays from 7 a.m. to 9 p.m. or weekends from 8 a.m. to 6:30 p.m. Eastern time.